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Abstract
Background: A six-dose antimalarial regimen of artemether-lumefantrine (A/L) may soon become one
of the most widely used drug combination in Africa, despite possible constraints with adherence and poor
absorption due to inadequate nutrition, and a lack of pharmacokinetic and effectiveness data.
Methods: Within a trial of supervised versus unsupervised A/L treatment in a stable Ugandan Plasmodium
falciparum transmission setting, plasma lumefantrine concentrations were measured in a subset of patients
on day 3 (C [lum]day3) and day 7 (C [lum]day7) post-inclusion. Predictors of lumefantrine concentrations
were analysed to show how both C [lum]day7 and the weight-adjusted lumefantrine dose affect 28-day
recrudescence and re-infection risks. The implications of these novel findings are discussed in terms of the
emergence of lumefantrine-resistant strains in Africa.
Results: C [lum]day3 and C [lum]day7 distributions among 241 supervised and 238 unsupervised patients
were positively skewed. Unsupervised treatment and decreasing weight-adjusted lumefantrine dose were
negatively associated with C [lum]day3. Unsupervised treatment and decreasing age showed strong negative
associations with C [lum]day7. Both models were poorly predictive (R-squared < 0.25). There were no
recrudescences in either arm, but decreasing lumefantrine dose per Kg resulted in up to 13-fold higher
adjusted risks of re-infection. Re-infections occurred only among patients with C [lum]day7 below 400 ng/
mL (p < 0.001).
Conclusion: Maintaining the present six-dose regimen and ensuring high adherence and intake are
essential to maximize the public health benefits of this valuable drug combination.
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Background
The fixed dose antimalarial combination of artemether-
lumefantrine (A/L) is a promising and efficacious artem-
isinin-based combination treatment (ACT) that could
play a key role in reducing the high mortality suffered by
African children with Plasmodium falciparum malaria. The
three day, six dose regimen of A/L is currently prioritized
by the World Health Organization as a replacement for
failing antimalarial monotherapies, notably chloroquine
and sulfadoxine-pyrimethamine (SP). Several countries
(e.g. Zambia, Kenya, Tanzania, South Africa, Niger, and
Uganda) have now adopted A/L as the first line antimalar-
ial. Clinical trials have shown A/L to be safe and highly
efficacious [1]. However, in routine practice, several draw-
backs may reduce its effectiveness. Absorption of the
longer-acting, lipophilic partner drug, lumefantrine, is
highly dependent on the intake of food, especially lipids.
Its oral bioavailability varied sixteen-fold in fasting
healthy Thai volunteers compared to volunteers who had
taken a fatty meal. Taking a light (500 calories, 10 g fat) or
'normal' (1,000 calories, 20 g fat) meal within one hour
either side of the first A/L dose increased lumefantrine
bioavailability by a mean factor of 48% and 108%, respec-
tively, compared to fluids alone[2]. In these volunteers,
the relative bioavailability increased three-fold with the
third and fourth doses compared to the first two doses
because appetite improved rapidly in parallel with clinical
recovery. There is also considerable inter-individual varia-
tion in the peak plasma lumefantrine concentration
(Cmax) in volunteers and in patients [2]. In Thai patients,
the lower and upper fifth percentile Cmax of the three day,
six dose regimen were 1,100 and 19,800 ng/mL respec-
tively, an eighteen-fold difference [3].
The spacing of each dose is also important according to
the manufacturer (Novartis Pharma, Basel, Switzerland).
The first and second doses should be taken eight hours
apart. The remaining doses (two doses on the subsequent
two days) should be taken 12 hours apart with the third
dose taken 24 hours after the first. To help with this com-
plex regimen, A/L is currently packaged in an illustrated,
patient-friendly blister. Assessment of this packaging in
Mbarara, Uganda resulted in high rates of adherence and
a day 3 median (range) lumefantrine concentration in
patients of all ages of 2,450 (600 to 11,400) ng/mL [4].
The median concentration in children under five, how-
ever, was significantly lower than in older children and
adults [4].
Outside the research setting, poor adherence might com-
pound the problems of poor lipid intake and dose spac-
ing, and further contribute to sub-optimal lumefantrine
blood concentrations. Dose ranging studies have estab-
lished that the key pharmacokinetic (PK) determinant of
cure for A/L is the area under the concentration time curve
(AUC) of the longer acting lumefantrine, and, therefore,
the time during which lumefantrine concentrations
exceed both the minimum parasiticidal (MPC) and mini-
mum inhibitory (MIC) concentrations of the parasites. In
multi-drug resistant areas of Thailand, the day 7 lumefan-
trine concentration was a useful surrogate for AUC. A con-
centration of less than 280 ng/ml was a useful predictor of
treatment failure and may approach the in vivo MIC of
parasites from this area [2,3]. Factors leading to a lowering
of the AUC will reduce the probability of cure and could
shorten the therapeutic lifespan of A/L, by exposing para-
sites to sub-therapeutic lumefantrine concentrations, thus
favouring the emergence of lumefantrine-resistant strains.
Pharmacokinetic studies of lumefantrine have been con-
ducted in Chinese, Thai and European adult patients and
in a very small number of children between 6 and 12 years
of age [2,3,5-7], but published data from sub-Saharan
Africa, where the drug is most likely to see widespread use,
are lacking. In particular, young children under five are
conspicuously absent from the literature. Our group pre-
viously reported a trial of supervised versus unsupervised
A/L for treatment of uncomplicated falciparum malaria in
Ugandan patients of all ages. Both methods of treatment
administration were highly effective, achieving cure rates
exceeding 95% [8]. Here, lumefantrine pharmacokinetic
findings from a subset of these patients are presented, and
their determinants and effects on novel infections during
28 days of follow up are examined.
Methods
Study procedures
Trial methods are detailed elsewhere [8]. Briefly, the study
was conducted in Mbarara, southwestern Uganda, an area
of multi-drug resistant P. falciparum [9,10]. Ethical
approval was obtained from Mbarara University of Sci-
ence and Technology and from the Uganda National
Council for Science and Technology. After obtaining writ-
ten informed consent, non-pregnant, uncomplicated
malaria patients with symptomatic P. falciparum mono-
infection (500 to 100,000/μL) were randomized to a six
dose regimen of either supervised or unsupervised A/L
(Novartis Pharma, Basel, Switzerland), according to body
weight: (i) one tablet (artemether 20 mg/lumefantrine
120 mg) per dose (10–14.9 Kg), (ii) two tablets/dose (15–
24.9 Kg), (iii) three tablets/dose (25–34.9 Kg), and (iv)
four tablets/dose (≥35 Kg). In the supervised arm, each
dose administration was directly observed for 30 minutes,
and the whole dose was repeated in case of vomiting. 300
mL milk (~10 g fat) and 30 g groundnuts (~13 g fat) were
given with each supervised dose. For small children, the
tablet was dissolved in water and spoon-fed, and the fat
source consisted of breast milk. Doses one and two were
given exactly eight hours apart, dose three was given at 8
a.m. the following morning (about 24 hrs after dose one),Malaria Journal 2006, 5:59 http://www.malariajournal.com/content/5/1/59
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and the remaining doses 12 hours apart. Unsupervised
patients received the first dose as above, but were given
the remainder of the blister pack for home administra-
tion, along with a standardized message on dose spacing
and appropriate food intake.
Patients were assessed on days 3, 7, 14, 21 and 28 for
safety and efficacy endpoints. Recurrent parasitaemias
between days 7 and 28 were analysed by a polymerase
chain reaction (PCR) comparing the pre- and post-treat-
ment genotypes of the parasite loci coding for the mero-
zoite surface proteins 1 and 2 (MSP-1 and MSP-2) and the
glutamate rich protein (GLURP)[11], so as to distinguish
new from recrudescent infections. Parasitological failure
was defined as any occurrence of PCR-confirmed recru-
descent parasitaemia during follow-up (irrespective of
symptoms).
Sampling in the trial was stratified to compare cure rates
in three age groups: under 5 years, 5–14 years, and 15 and
above. In each arm and age group, 70 patients per group
were randomly sampled for plasma lumefantrine levels
on days 3 and 7 (i.e. 210 supervised and 210 unsuper-
vised). These patients were selected using simple random
sampling from the treatment allocation lists. Venous
blood (4 mL) was collected in heparinized vacutainers
during the days 3 and 7 morning visits. Blood samples
were immediately centrifuged and plasma stored in cryo-
tubes at -70°C up to and including transport to Novartis
Pharma in Paris, France, where plasma lumefantrine lev-
els were determined blindly using a previously described
high performance liquid chromatography (HPLC)
method. This method detects C [lum] values > 5 ng/mL,
with coefficients of variation of 1.8 to 4.2% [12].
Statistical analysis
Data were double-entered on EpiData 3.0 (the Epidata
Association, Odense, Denmark), and analysed using Stata
8.2 (Stata Corp., College Station, Texas, USA). Lumefan-
trine concentrations were compared by arm within age
groups using the unpaired t-test, and C [lum]day3 and C
[lum]day7 were correlated using Spearman's rho correla-
tion coefficients. The association between baseline patient
variables and C [lum]day3 or C [lum]day7 was then analysed
in separate multivariate linear regression models, pro-
ceeding as follows. First, the dependent variable (lume-
fantrine concentration) was transformed into its square
root (C [lum]day3) or natural logarithm (C [lum]day7) so as
to normalize distributions. For each patient, the weight-
adjusted lumefantrine dose prescribed in mg/Kg was then
calculated (= number of tablets per dose × 6 doses × 120
mg/dose/bodyweight in Kg), and categorized as <50, 50–
64, 65–79, and ≥80 mg/Kg, which corresponded almost
exactly to 1 SD intervals away from the mean of 64 mg/Kg.
Certain baseline parameters were selected as independent
explanatory variables for inclusion in the models: (i) if
they appeared likely to represent plausible biological or
epidemiological predictors (referral from hospital outpa-
tient department vs. outlying clinics; gender; history of
anorexia, nausea, vomiting, abdominal pain, diarrhoea,
or fatigue; hepatomegaly; day 0 axillary temperature; asex-
ual parasite density; haemoglobin; presence of concomi-
tant febrile illness; and co-administration of antibiotics or
antihelminthics); or (ii) if they were associated with the
outcome at the p < 0.20 level in a univariate analysis (his-
tory of dizziness, gametocytaemia). The regression was
performed on all selected explanatory variables, and non-
significant ones were then progressively removed.
Dropped variables were then re-added one by one and
retained if they affected the model or were associated sig-
nificantly with the outcome. Weight-adjusted lumefan-
trine dose, age group and arm were forced into all final
models (this was done since the association of these vari-
ables with the outcome seemed very biologically plausi-
ble; however, alternative models were also constructed
without forcing these variables). After searching for plau-
sible interactions and assessing the effect of influential
data points, model assumptions were tested, including
normality of residuals, linearity between dependent and
explanatory variables, lack of collinearity among explana-
tory variables, and constant variance (homoscedasticity).
The association between the weight-adjusted lumefan-
trine dose and the risk of re-infection during the 28 days
of follow-up was then analysed by the Cox proportional
hazards model, controlling for potential confounders. All
enrolled patients who were analysable by intention to
treat (ITT) were included in this analysis [8]. Among base-
line explanatory variables considered potential confound-
ers (hospital attendance, gender, day 0 axillary
temperature, splenomegaly, asexual density, gametocytae-
mia, and haemoglobin), those with a p < 0.20 in the uni-
variate analysis of the outcome (re-infection) were
selected. The final model was constructed manually as
described above. After searching for interactions, the pro-
portional hazards assumption that relative risks do not
vary with time was tested.
Finally, the Log-Rank test was used to compare the proba-
bility of survival (i.e. of remaining re-infection free) from
day 7 as a function of the C [lum]day7 levels: <200, 200–
399, 400–599, and ≥600 ng/mL.
Results
Pharmacokinetics
Baseline characteristics of the 479 patients who had at
least one pharmacokinetic sampling are shown in Table 1.
No C [lum]day3 results were available for 22 of these
patients (4.6%), and no C [lum]day7 results for were avail-
able for 24 (5.0%). A further five patients with outlier val-Malaria Journal 2006, 5:59 http://www.malariajournal.com/content/5/1/59
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ues were excluded from day 7 analyses. Characteristics of
patients with missing data did not significantly differ from
those of the analysable sample (data not shown).
Lumefantrine concentration distributions were skewed to
the right. There was marked inter-individual variability in
C [lum]day3 and C [lum]day7 for all age groups and arms
(Figures 1 and 2). Using the fifth and 95th centile concen-
trations, the variability in each age group (<5, 5–14, ≥15
y) was 13 200/857 (15.4-fold), 12 100/978 (12.4) and 10
700/692 (15.5) respectively for C [lum]day3 and 718/58
(12.4), 824/86 (9.6) and 870/101 (8.6) for C [lum]day7.
Median supervised versus unsupervised C [lum]day3 values
(ng/mL) were 7040 vs. 2700 (<5 y), 5965 vs. 3310 (5–4
y), and 5320 vs. 3490 (≥15 y) (p < 0.001 for all compari-
sons). Corresponding median C [lum]day7 values were 330
vs. 156, 402 vs. 249, and 382 vs. 281 (p < 0.001 for all
comparisons). C [lum]day3 and C [lum]day7 showed good
correlation (Rho = 0.70, p < 0.001), with no differences
across age groups or arms. 70/241 (29.0%) supervised
and 140/238 (58.8%) unsupervised patients had a C
[lum]day7 below 280 ng/mL.
In multivariate linear models, unsupervised treatment
had a strong negative association with C [lum]day3 (Table
2). A history of vomiting was also a negative explanatory
variable and a negative trend was apparent for decreasing
weight-adjusted lumefantrine dose. Female gender was
positively associated. No clear association of C [lum]day3
with age was noted. In the model for C [lum]day7 (Table
3), unsupervised treatment retained its strong negative
effect. Age <5 y also had a strong negative association. A
Box plots of day 7 lumefantrine concentrations by age group  and arm Figure 2
Box plots of day 7 lumefantrine concentrations by 
age group and arm. Each box displays the median, upper 
and lower quartiles of the respective distribution. Box whisk-
ers represent the maximum and minimum range excluding 
any extreme outliers (shown as dots).
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Table 1: Baseline characteristics of patients sampled for lumefantrine pharmacokinetics.
Variable Supervised arm Unsupervised arm
< 5 years 5–14 years ≥15 years < 5 years 5–14 years ≥15 years
number sampled 70 92 79 68 91 79
sex ratio (M/F) 1.9 (46/24) 0.9 (43/49) 0.8 (36/43) 1.1 (36/32) 0.7 (37/54) 0.5 (28/51)
median age (range) 3 (1–4) 7 (5–14) 25 (15–60) 3 (1–4) 8 (5–14) 25 (15–80)
parasite density 
(median, IQR)
12 344 (4232–33 
799)
15 668 (3750–
36523)
6256 (1957–15 
980)
22 777 (11 290–51 
775)
11 367 (3449–32 
475)
6156 (2749–19 
459)
axillary 
temperature (°C) 
(mean, IQR)
37.5 (36.7–38.4) 37.3 (36.4–38.0) 36.7 (36.0–37.5) 37.7 (36.7–38.9) 37.1 (36.1–37.8) 36.7 (36.1–37.2)
weight-adjusted 
lumefantrine dose 
(mg/Kg) (mean, 
range)
66 (48–96) 72 (48–96) 53 (32–76) 68 (48–96) 73 (51–96) 54 (35–80)
Box plots of day 3 lumefantrine concentration by age group  and arm Figure 1
Box plots of day 3 lumefantrine concentration by age 
group and arm. Each box displays the median, upper and 
lower quartiles of the respective distribution. Box whiskers 
represent the maximum and minimum range excluding any 
extreme outliers (shown as dots).
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history of dizziness and attendance of the regional referral
hospital were both associated with a lower C [lum]day7.
The trend for weight-adjusted lumefantrine dose was less
clear; values between 50 and 79 mg/Kg were associated
with lower C [lum]day7 but no such association was shown
for the under 50 mg/Kg group. Gametocyte carriage at
inclusion was positively associated with C [lum]day7. No
significant interactions between age, lumefantrine dose
Table 3: Final main effects linear model of the association between baseline explanatory variables and day 7 lumefantrine 
concentration in ng/mL (433 patients).
Variable Coefficient 95%CI p-value p-value (trend)
lower upper
referred from hospital 
OPD (vs. from 
outlying clinics)
-198.3 -316.9 -63.1 0.005
unsupervised 
treatment
-463.3 -536.8 -381.0 <0.0001
age
≥15 years [reference] <0.0001
5–14 years -54.6 -233.3 158.4 0.591
< 5  y e a r s - 3 5 7 . 9- 4 8 3 . 8- 2 0 8 . 6< 0 . 0 0 0 1
lumefantrine dose 
(mg/Kg)
≥80 [reference] 0.375
65–79 -168.6 -319.3 9.1 0.062
50–64 -187.5 -348.4 5.1 0.056
<50 -36.1 -287.0 286.8 0.806
gametocytaemic at 
inclusion
395.2 89.5 775.7 0.009
history of dizziness at 
inclusion
-284.4 -414.9 -131.1 0.001
constant
adjusted R2: 0.219
p-value for goodness of fit: <0.0001
Table 2: Final main effects linear model of the association between baseline explanatory variables and day 3 lumefantrine 
concentration in ng/mL (456 patients).
Variable Coefficient 95%CI p-value p-value (trend)
lower upper
female gender 791.4 125.2 1493.3 0.019
unsupervised 
treatment
-2538.2 -2995.0 -2046.8 <0.0001
age
≥15 years [reference] 0.358
5–14 years 322.5 -657.8 1388.6 0.530
<5 years 462.3 -478.7 1480.2 0.345
lumefantrine dose 
(mg/Kg)
≥80 [reference] 0.033
65–79 -463.2 -1336.2 488.2 0.329
50–64 -1009.2 -1892.5 -35.4 0.043
<50 -1237.2 -2386.6 79.5 0.064
history of vomiting at 
inclusion
-688.6 -1294.1 -44.8 0.036
constant 5778.1 4313.1 7457.0
adjusted R2: 0.164
p-value for goodness of fit: <0.0001Malaria Journal 2006, 5:59 http://www.malariajournal.com/content/5/1/59
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and arm were found. Overall, however, both models
accounted for only a small fraction of the observed varia-
bility in lumefantrine concentrations (adjusted R2 values
< 0.25).
Re-infection risk
Of 957 patients enrolled in the trial, 946 were ITT-eligible
and included in the Cox proportional hazards model. All
patients were parasite negative by day 3. By day 28, there
were 33 PCR-confirmed re-infections but no parasitologi-
cal failures. Total person-time of follow up was 26,005
person-days, giving a re-infection rate of 0.00127 (33/
26,005) person-days, or 0.46 per person-year. All re-infec-
tions occurred on or after day 21, and 22/34 (64.7%) on
day 28. After adjusting for age and arm, decreasing weight-
adjusted lumefantrine dose was associated significantly
with a higher hazard of re-infection, although confidence
intervals were wide (Table 4). In the subset of patients
with an available C [lum]day7 result, the probability of re-
infection increased significantly as C [lum]day7 decreased,
and no re-infections occurred in patients with levels ≥400
ng/mL (Table 5). We could not perform a multivariate
regression, because C [lum]day7 lies in the causal pathway
between the dependent (re-infection) and other explana-
tory variables. However, stratifying by age group, the only
strong confounder detected by the Cox model, also
showed a significant risk of re-infection with declining age
(Table 5).
Discussion
This study has generated new and valuable information
on the pharmacokinetics and dose-dependent effects of A/
L in malaria patients of all ages at a sub-Saharan African
site experiencing stable transmission of multi-drug resist-
ant P. falciparum, namely the kind of setting where highly
efficacious ACTs like artemether-lumefantrine are needed
and will probably be most beneficial.
In these Ugandan patients, we found that both C
[lum]day3  and C [lum]day7  displayed up to fifteen-fold
inter-individual variability, consistent with other studies
[13]. Median lumefantrine levels were significantly lower
in unsupervised patients, but these differences did not
affect cure rates at 28 days [8]. The C [lum]day3 concentra-
tions in the unsupervised patients were similar to those
found in a previous adherence study in Mbarara [4].
C [lum]day3 and C [lum]day7  correlated well, but were
affected differently by certain baseline patient variables.
The peak lumefantrine concentration after the three day
regimen occurs some 70 hours after intake of the first dose
[3,13]. As a close surrogate, we sampled patients on day 3,
namely at approximately 72 hours. The C [lum]day3 may
represent mostly drug intake, absorption from the small
bowel and distribution: this could explain why unsuper-
vised treatment, vomiting and a lower weight-adjusted
lumefantrine dose were associated with a reduced C
[lum]day3. By contrast, the C [lum]day7 could be the result
of drug metabolism and elimination (clearance), princi-
pally by the liver and biliary system: children under five
had significantly lower C [lum]day7, possibly because of
enhanced metabolism and clearance. Interestingly, age
was not a significant explanatory factor for the C [lum]day3
in this study, a contrasting finding with the A/L adherence
study [4]. The associations of female gender with C
[lum]day3 and dizziness at baseline with C [lum]day7 are
harder to explain, and might be spurious results because
of multiple significance tests. In Thai patients, age, weight,
and gender were not associated with any of the main PK
parameters but the trial did not include children of less
than six years of age [3].
Despite highlighting these interesting associations, on the
whole our models did not satisfactorily explain the vari-
ance in C [lum]. Previous studies have shown that the
large effect on lumefantrine PK of lipid intake, which our
Table 4: Cox proportional hazards model of relative hazards of re-infection during 28 day follow-up (946 patients).
Variable Relative hazard 95%CI p-value p-value (trend)
lower upper
unsupervised 
treatment
1.77 0.82 3.79 0.144
age group <0.001
15 years and above 1.00 [reference]
5–14 years 4.05 1.10 14.94 0.036
<5 years 8.44 2.71 26.27 <0.001
lumefantrine dose 
(mg/Kg)
0.003
≥80 1.00 [reference]
65–79 7.50 0.95 59.12 0.056
50–64 13.95 1.82 106.65 0.011
<50 12.72 1.08 150.22 0.043Malaria Journal 2006, 5:59 http://www.malariajournal.com/content/5/1/59
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study was not designed to measure, far outweighs other
factors [13].
These findings should be generalized with caution. In
Asia, Chinese patients had higher peak lumefantrine on
day 3 than Thai patients treated with the same A/L regi-
men (four tablets over 48 hours) who in turn had higher
values than European patients [3,13]. Median C [lum]day3
results in our study are broadly consistent with those of
Thai patients but lower than those in Chinese patients,
even though patients in this study received the six dose
regimen. Apart from food intake, pharmacogenetic factors
(e.g. the wide variability in CYP 3A, the cytochrome P450
enzyme responsible for artemether and lumefantrine
metabolism [3,13]) and differences in nutritional status
in African patients may be important and are avenues for
further research.
In the multi-drug resistant areas of western Thailand, a
day 7 lumefantrine concentration below 280 ng/mL was a
reasonable predictor of treatment failure. In this study,
there were no treatment failures despite day 7 lumefan-
trine concentrations <280 ng/ml in 45% of all patients, a
finding probably due to the high parasite sensitivity to
lumefantrine in Uganda.
By contrast, a day 7 lumefantrine concentration of <400
ng/ml and receiving a lower dose per Kg of lumefantrine
were risk factors for re-infection during follow-up; this
risk was thirteen-fold higher in patients receiving less than
65 mg/Kg compared to those receiving ≥80 mg/Kg. Most
re-infections became visible in the blood 21 to 28 days
after start of treatment, when lumefantrine levels would
be expected to be very low, and sub-therapeutic. In our
study almost 50% (134/286) of children under 5 years
received less than 65 mg/Kg of lumefantrine; these chil-
dren also experienced an additional age-related, eight-fold
higher risk of re-infection compared to adults. Parasite re-
infection has received far less attention than recrudes-
cence. Nonetheless, in the era of highly efficacious ACTs
like A/L, preventing re-infections may become an impor-
tant public health issue, especially in children under five
in stable high transmission areas and individuals during
malaria epidemics; in both groups, re-infections cause
high malaria morbidity and mortality. Our findings sug-
gest that, in routine practice, low adherence and poor
lipid intake could result in re-infection rates that would
negate the benefits of high A/L efficacy.
This in vivo study extended to only 28 days. Had patients
been monitored for 42 days, as recommended by some,
we could have detected later recrudescences [14]. The
sample of patients may not have been fully representative
of a typical outpatient population because the trial had
specific entry criteria, and the study environment may
have modified patients' adherence patterns. The study was
not designed to estimate pharmacokinetic parameters
such as peak concentration and terminal half-life. Lume-
fantrine levels could only be measured on days 3 and 7.
Both of these time point measures are crude surrogates of
the AUC, the key pharmacokinetic determinant of cure.
Further modelling in different settings will be required to
determine how useful these markers are.
Despite the limitations of this study, it is clear that a high
day 28 A/L cure rate can be achieved despite low plasma
lumefantrine levels, even among unsupervised patients.
This apparently favourable situation may, however, set up
conditions for the selection of resistant parasites, espe-
cially in young children who not only harbour high bio-
mass infections but also achieve the lowest day 7
lumefantrine levels. The prevention of de novo resistance
to ACT combinations is clearly a crucial consideration that
probably overrides the desirability of preventing novel
infections through a post-treatment prophylactic effect
[15]. In this regard, adherence to the six dose A/L regimen,
now recommended by WHO, will be critical. Other effica-
cious ACTs may also be unable to significantly prevent re-
Table 5: Log-rank test of probability of survival (i.e. remaining re-infection free), by age group and day 7 lumefantrine concentration.
C 
[lum]day
7 (ng/mL)
< 5 years 5–14 years ≥15 years Total
nc nr psurv nc nr psurv nc nr psurv nc nr psurv
<200 47 5 0.889 32 4 0.871 33 2 0.938 112 11 0.898
200–399 51 3 0.940 77 2 0.987 63 2 0.968 191 7 0.968
400–599 20 0 1.000 34 0 1.000 33 0 1.000 87 0 1.000
≥600 11 0 1.000 30 0 1.000 21 0 1.000 62 0 1.000
p-value 
(trend):
0.002 0.283 0.399 <0.001
nc = number in category nr = number of re-infections psurv = probability of survivalMalaria Journal 2006, 5:59 http://www.malariajournal.com/content/5/1/59
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infections in high transmission areas, where the simulta-
neous deployment of an effective ACT and insecticide-
impregnated bed nets is needed.
Conclusion
A/L is a precious tool in the available arsenal against
malaria morbidity and mortality, especially in African
children. Although it needs to be made widely available to
populations in need, care should also be taken to avoid
creating favourable conditions for the emergence of lume-
fantrine-resistant malaria strains [16]. Further research is
needed to explore the determinants of sub-optimal lume-
fantrine plasma levels and how to overcome these. Health
systems deploying A/L should develop and strengthen
strategies to maximize the effectiveness of the six-dose reg-
imen, for which both high adherence and appropriate
food intake are proven imperatives. Monitoring lumefan-
trine resistance should be an essential element of wide-
spread implementation of this valuable drug
combination. New studies should explore the synergistic
effects of using ACTs and insecticide-impregnated bed
nets.
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